Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438).
about
Vonoprazan-based therapy for Helicobacter pylori eradication: experience and clinical evidenceBenzimidazole covalent probes and the gastric H(+)/K(+)-ATPase as a model system for protein labeling in a copper-free settingNovel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance.Vonoprazan: first global approval.The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.Protonated form: the potent form of potassium-competitive acid blockersRandomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.Randomised clinical trial: a dose-ranging study of vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the treatment of erosive oesophagitis.Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind studyVonoprazan 20 mg vs lansoprazole 30 mg for endoscopic submucosal dissection-induced gastric ulcers.Pharmacokinetic Drug-Drug Interactions Between Vonoprazan and Low-Dose Aspirin or Nonsteroidal Anti-inflammatory Drugs: A Phase 2, Open-Label, Study in Healthy Japanese MenA Comparative Study of a New Class of Gastric Acid Suppressant Agent Named Vonoparazan versus Esomeprazole for the Eradication of Helicobacter pylori.Efficacy of a potassium-competitive acid blocker for improving symptoms in patients with reflux esophagitis, non-erosive reflux disease, and functional dyspepsia.Evolving pharmacological approaches in gastroesophageal reflux disease.Evaluation of the Efficacy and Safety of Vonoprazan in Patients with Nonerosive Gastroesophageal Reflux Disease: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study.Randomised clinical trial: safety, tolerability, pharmacokinetics and pharmacodynamics of repeated doses of TAK-438 (vonoprazan), a novel potassium-competitive acid blocker, in healthy male subjects.Characteristics of the Novel Potassium-Competitive Acid Blocker Vonoprazan Fumarate (TAK-438).Vonoprazan for treatment of gastroesophageal reflux: pharmacodynamic and pharmacokinetic considerations.Effect of Vonoprazan, a Potassium-Competitive Acid Blocker, on the 13C-Urea Breath Test in Helicobacter pylori-Positive Patients.Vonoprazan fumarate for the management of acid-related diseases.Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single Rising TAK-438 (Vonoprazan) Doses in Healthy Male Japanese/non-Japanese Subjects.Identification, characterization, and high-performance liquid chromatography quantification of process-related impurities in vonoprazan fumarate.Helicobacter pylori Eradication with Proton Pump Inhibitors or Potassium-Competitive Acid Blockers: The Effect of Clarithromycin Resistance.Vonoprazan versus conventional proton pump inhibitor-based triple therapy as first-line treatment against Helicobacter pylori: A multicenter retrospective study in clinical practice.Vonoprazan prevents bleeding from endoscopic submucosal dissection-induced gastric ulcers.The binding selectivity of vonoprazan (TAK-438) to the gastric H+, K+ -ATPase.The effects of varying acidity on Helicobacter pylori growth and the bactericidal efficacy of ampicillin.Vonoprazan: MarKed Competition for PPIs?Gastric acid-dependent diseases: a twentieth-century revolution.Disposition and metabolism of TAK-438 (vonoprazan fumarate), a novel potassium-competitive acid blocker, in rats and dogs.Hypergastrinemia in Long-Term Use of Proton Pump Inhibitors.Safety of first-line triple therapy with a potassium-competitive acid blocker for Helicobacter pylori eradication in children.Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases.Vonoprazan prevents low-dose aspirin-associated ulcer recurrence: randomised phase 3 study.Vonoprazan fumarate, a novel potassium-competitive acid blocker, in the management of gastroesophageal reflux disease: safety and clinical evidence to date.Vonoprazan prevents ulcer recurrence during long-term NSAID therapy: randomised, lansoprazole-controlled non-inferiority and single-blind extension study.Rationale and design of the VISION study: a randomized, open-label study to evaluate the long-term safety of vonoprazan as maintenance treatment in patients with erosive esophagitis.Effect of Multiple Oral Doses of the Potent CYP3A4 Inhibitor Clarithromycin on the Pharmacokinetics of a Single Oral Dose of Vonoprazan: A Phase I, Open-Label, Sequential Design Study.In vitro metabolism of TAK-438, vonoprazan fumarate, a novel potassium-competitive acid blocker.Radiographic Localization Study of a Novel Potassium-Competitive Acid Blocker, Vonoprazan, in the Rat Gastric Mucosa.
P2860
Q28072552-A9C6BBD9-0134-4187-99CB-64EADC3EE6BAQ28833519-2C34A771-DE58-4235-AB0C-0EFA39C3C4F0Q33639114-7D4C8450-06E5-40EF-AC36-1424AB4DCA30Q34465959-A5277BA7-D768-4782-A4C6-F633CA99A24BQ34494081-A6D14F22-B8A5-4A53-9FFD-ABAFBB34751AQ35171617-2D351D07-904C-4D1D-98F3-6FAC6611F6ACQ36536693-BC174E74-33EE-4811-9895-36BC9D6B1A75Q37238180-E3392F02-8AD5-4DF3-85F4-084F5C05FE92Q37282589-E8290FF3-73B5-4278-A807-D954B14BC91FQ37421468-C1BF3552-DBD3-4CA1-A1AA-45CF2B796E1FQ37553533-CBCCA835-EF08-418C-886F-32C97077BB3BQ37697753-5D59A599-84B0-4EBD-B470-4186A5E6EB0EQ37701115-80D22072-EDFB-438A-8460-B74EF757BE8EQ38029727-FE52960A-25A0-45F4-A448-D4B485BDC2D3Q38381807-595E7764-8286-4F7C-ACFF-6E906A3EA096Q38415822-5F6690E4-87F4-442E-87D2-25E9932A228FQ38861693-7388DCEC-D292-4D7F-9CB3-BEFDE127E301Q38900694-FB5A61C6-886F-4C56-BDA3-39022014750DQ39022922-EBF49E3B-6815-4B44-911A-ACD6D1FDF2F7Q39402205-907368BA-A66E-4CC6-870F-2566CB4A46FDQ39746768-FBA2C0E1-A1E2-451B-9D87-2BA65B8EF985Q40025927-D90D5525-0947-4B25-A320-0B428A5F1A3DQ40502852-20D9EA35-8D2D-4367-97FF-7D3E03CAE0E9Q40572311-B209C490-6E74-4A05-A17E-22CC93E72D4FQ40597694-214E6D5D-8FDA-4CAE-9A7B-A7147FDA568EQ42023861-ED4126CD-7B2C-4EE3-9CFE-938FE709DF13Q42023922-E5CE04AC-C2B1-4C6F-B5CC-E25224F47755Q42535426-F6C1D45B-8E6C-43B2-916E-602458B924B7Q46029814-24FBDB7E-72F8-425A-AEFF-006C3502DD74Q46542551-2542D065-9F51-42CC-BC89-8AC3C38EC31EQ47197069-784A8E0C-828A-4F6B-8B2F-09A43D25B3ADQ47225018-DE3E8D5F-4C93-48A6-B993-67DFFB04B1B5Q48339888-5A730B56-EBC6-4E42-9F40-F18DAC9048F1Q49355765-6A169C4D-5EE4-4E57-8B1E-88B9F63504A3Q49447901-0937772E-A9E3-4CE9-874D-BF0F42988F2EQ49502634-87B267A9-5305-4F24-BA51-3BC44AA179FDQ49727148-3FF9C499-B31A-4DAE-A64D-E6884406465CQ51023374-91A63851-1C82-4FC0-9D3B-D75EB480CC10Q51642470-BECFE6B5-73E1-4581-B9F9-93FA9B4DF3BCQ52881408-3D191EC6-3944-45F4-ADEA-C8BB65A1B5D8
P2860
Characterization of a novel potassium-competitive acid blocker of the gastric H,K-ATPase, 1-[5-(2-fluorophenyl)-1-(pyridin-3-ylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine monofumarate (TAK-438).
description
2011 nî lūn-bûn
@nan
2011 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Characterization of a novel po ...... namine monofumarate (TAK-438).
@ast
Characterization of a novel po ...... namine monofumarate (TAK-438).
@en
type
label
Characterization of a novel po ...... namine monofumarate (TAK-438).
@ast
Characterization of a novel po ...... namine monofumarate (TAK-438).
@en
prefLabel
Characterization of a novel po ...... namine monofumarate (TAK-438).
@ast
Characterization of a novel po ...... namine monofumarate (TAK-438).
@en
P2093
P2860
P356
P1476
Characterization of a novel po ...... namine monofumarate (TAK-438).
@en
P2093
David Strugatsky
Elmira Tokhtaeva
George Sachs
Jai Moo Shin
Keith Munson
Nobuhiro Inatomi
Olga Vagin
P2860
P304
P356
10.1124/JPET.111.185314
P407
P577
2011-08-09T00:00:00Z